-
-
-
-
-
-
-
FDA grants fast track status to Oncolytics' pelareorep for anal cancer
-
-
-
-
-
-
-
Oncolytics Biotech completes incorporation change from Canada to Nevada
-
-
-
-
-
-
-
Oncolytics reports 33% response rate in colorectal cancer study
-
-
-
-
-
-
-
Oncolytics Biotech expands GOBLET cancer trial to US sites
-
-
-
-
-
-
-
Oncolytics Biotech reports survival data for pelareorep cancer therapy
-
-
-
-
-
-
-
Oncolytics Biotech (ONCY) Misses Q3 EPS by 2c
-
-
-
-
-
-
-
Oncolytics Biotech (ONCY) Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
-
479,044 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


